0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Nifedipine on Tubular Handling of Uric Acid in Transplanted Kidney on Cyclosporine A Treatment

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hyperuricemia resulting from tubular urate transport defects is a well-known nephrotoxic effect of cyclosporine A (CyA) on renal blood perfusion in organ recipients. The aim of this study was to define the mechanism of the tubular urate transport defect in hyperuricemic renal graft recipients on CyA and to evaluate the effect of nifedipine retard administration on this tubular dysfunction. Tubular uric acid transport was evaluated by the probenecid test in 17 hyperuricemic (group 1) and 6 normouricemic (group 2) renal graft recipients treated with CyA. Maximal urate excretion after probenecid administration was 25.5 ± 4.6 versus 42.5 ± 7.7% (p < 0.001) and postsecretory urate reabsorption was 79.2 ± 8.3 versus 78.5 ± 9.7% (NS), respectively. The effects of nifedipine retard on renal urate transport were evaluated in 6 hyperuricemic patients. Seven days of nifedipine therapy did not significantly decrease mean serum uric acid levels (7.7 ± 1.6 to 7.1 ± 1.1 mg/dl) nor increase urate clearance (3.8 ± 1.3 to 4.7 ± 1.6 ml/min/1.73 m<sup>2</sup>). The uricosuric effect of probenecid was manifested by an increase in tubular urate transport from 25.5 ± 4.6 to 37.3 ± 7.2%, p < 0.01, paralleled by an increase in postsecretory urate reabsorption from 20.5 ± 3.7 to 31.4 ± 5.7% (p < 0.003). Postsecretory reabsorption expressed as a percentage of secreted urate in both evaluations did not differ significantly (80.3 ± 6.2 vs. 84.4 ± 3.1%). These results suggest that hyperuricemia in kidney recipients on CyA is a consequence of decreased tubular urate secretion, and administration of nifedipine retard in these patients equally increased both tubular secretion and back-reabsorption of secreted uric acid.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1995
          1995
          18 December 2008
          : 70
          : 1
          : 77-82
          Affiliations
          Department of Nephrology, Dialysis and Kidney Transplantation, Child Health Center, Warsaw, Poland
          Article
          188548 Nephron 1995;70:77–82
          10.1159/000188548
          7617121
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article